Skip To Content

Thought leadership on the clinical impact on workers' compensation and auto no-fault.

Recent blog posts

October 29, 2019
The U.S. Food and Drug Administration (FDA) reports that sales for the abuse-deterrent opioid analgesic, Embeda® (morphine sulfate and naltrexone extended-release capsules), manufactured by Pfizer Pharmaceuticals, will cease on November 15, 2019. Read more...
October 22, 2019 · Clinical Connection team
What you need to know about the Zantac and generic ranitidine recalls Read more...
August 30, 2019 · Clinical Connection team
On August 15, 2019, the U.S. Food and Drug Administration (FDA) announced that Pfizer Inc. issued a voluntary recall for two lots of Relpax® (eletriptan) 40 mg tablets to the patient level. Read more...
August 19, 2019 · Optum for Workers' Compensation
On September 18, 2019, Novartis announced it is stopping the distribution of its Sandoz division’s ranitidine, generic for Zantac®, until further notice. Read more...
August 06, 2019 · Clinical Connection team
The New York State Workers Compensation Board (WCB) has released information on how to access and use the Drug Formulary Prior Authorization System. Read more...
April 29, 2019 · Optum for Workers' Compensation
On April 19, the U.S. Food and Drug Administration (FDA) approved the first generic for Narcan® Nasal Spray, the life-saving medication used for the emergency treatment of opioid-related overdose. Read more...
April 29, 2019 · Optum for Workers' Compensation
The U.S. Food and Drug Administration (FDA) issued a safety communication in early April that requires changes to prescribing information for opioid analgesics used in outpatient settings. Read more...
<< Previous      Next >>
Page 2 of 3

Subscribe today to receive our latest blogs, articles and more.

Subscribe now button

Download the latest
Pharmacy Resource Guide

Pharmacy Resource Guide